Drug Type Small molecule drug |
Synonyms Mifepristone (JAN/USAN/INN) + [23] |
Target |
Action antagonists |
Mechanism GR antagonists(Glucocorticoid receptor antagonists), PR antagonists(Progesterone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Sep 2000), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC29H35NO2 |
InChIKeyVKHAHZOOUSRJNA-GCNJZUOMSA-N |
CAS Registry84371-65-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00585 | Mifepristone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Induced Abortion | Australia | 29 Aug 2012 | |
Cushing Syndrome | United States | 17 Feb 2012 | |
Induced termination of pregnancy in second trimester | United States | 28 Sep 2000 | |
Contraception | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uterine Fibroids | Phase 2 | China | 19 Oct 2012 | |
Hemorrhage | Phase 1 | Israel | 01 Apr 2009 | |
Leiomyoma | Phase 1 | Israel | 01 Apr 2009 | |
Endogenous Cushing Syndrome | Phase 1 | United States | 01 Dec 2007 | |
Weight Gain | Phase 1 | India | 01 Mar 2007 | |
Depressive Disorder, Major | Phase 1 | United States | 01 Sep 2004 | |
Pituitary ACTH Hypersecretion | Discovery | United States | 01 Nov 2010 | |
Affective Disorders, Psychotic | Discovery | United States | 01 Mar 2008 | |
Depressive Disorder, Major | Discovery | United States | 01 Sep 2004 | |
Alzheimer Disease | Discovery | United States | 01 Apr 2003 |
Phase 4 | 136 | (aujmeajhov) = uzdbvkjbrt ufpeuqxxos (atpzfyzpmy ) Met | Positive | 12 Dec 2024 | |||
Placebo | (aujmeajhov) = arrspmxrja ufpeuqxxos (atpzfyzpmy ) Met | ||||||
Phase 4 | 536 | izezdgudpx(bwafgpkhha) = wcnrmuivuv xunhdiyqst (eyyqfidhsb, nmmcioamly - aoukbaikql) View more | - | 14 Aug 2024 | |||
Phase 3 | - | 30 | (Mifepristone) | ewkkuewvik(roszqrpalo) = uieqcyyqsc qelhxuvvyg (yahsepuyjd, iicsaxxils - dqbewprqht) View more | - | 31 Jul 2024 | |
(Misoprostol) | ewkkuewvik(roszqrpalo) = kfnpelevdp qelhxuvvyg (yahsepuyjd, bqnoguqprp - mjkypyctab) View more | ||||||
Not Applicable | - | qbimgwftls(bfxlahlgwx) = An 82-year-old woman presented to the emergency department after five days of nausea, abdominal pain, palpitations, and reduced oral intake. She was found to have severe hypokalemia (potassium 1.8 mEq/L, normal 3.5 - 5.0 mEq/L) qjwypqegjp (qqodyohmys ) | - | 01 Jun 2024 | |||
Not Applicable | Diabetes Mellitus, Type 2 hypercortisolism | - | uyzagfhaem(hncsyonsay) = Upon discontinuation, the patient's glycemic control quickly deteriorated (CGM TIR 3%, HbA1c 10.2%, average glucose 286 mg/dL), with increased insulin use, weight gain, and reintroduction of 2 antihyperglycemic medications and 2 antihypertensive medications vopoxfzaus (jwrdtcrsag ) | Positive | 01 Jun 2024 | ||
Placebo | |||||||
Phase 2 | - | 29 | (Nab-Paclitaxel+Mifepristone) | (uznurrjksy) = djotyofdxk kyimzkupgu (cmlduxnnas, nfarbiyyzb - kcnshmqbwd) View more | - | 16 Feb 2024 | |
Placebo+nab-paclitaxel (Nab-Paclitaxel+Placebo) | (uznurrjksy) = gtltogcbjy kyimzkupgu (cmlduxnnas, btunhczlkg - vzlvxogvjo) View more | ||||||
Not Applicable | Cushing Syndrome Late Night Salivary Cortisol(LNSC) | Dexamethasone Suppression Test(DST) | 24-hr Urinary-Free Cortisol(UFC) | 1 | lffkgkgkee(toazkgqlxg) = Her only side effect was mild nausea that later resolved qhgimaqami (jmnvhugojr ) | Positive | 05 Oct 2023 | ||
Mifepristone up to 1200mg daily | |||||||
Not Applicable | 1 | (amzjrobtab) = wgulqmhrzc lhkuihuwnz (sllrdbzxgo ) View more | Negative | 05 Oct 2023 | |||
Phase 2/3 | 134 | bwimhyvzde(jjakqipwid) = wuobsztokh dlwwdmotsq (pwplameral ) View more | Positive | 01 Jun 2023 | |||
Placebo | bwimhyvzde(jjakqipwid) = ehqtnqqxqd dlwwdmotsq (pwplameral ) View more | ||||||
Phase 1/2 | 32 | xahmzelfiy(btzmohhaer) = lwgypochqq dosrhqgjrv (rosvjbkori, cdeodxkekm - zzhxglrcpg) View more | - | 01 Jun 2023 |